Market Closed -
Nasdaq
04:00:00 2024-05-20 pm EDT
|
5-day change
|
1st Jan Change
|
2.18
USD
|
-2.68%
|
|
+0.93%
|
+24.56%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
9.049
|
9.655
|
16.13
|
10.65
|
7.915
|
9.322
|
-
|
-
|
Enterprise Value (EV)
1 |
9.049
|
9.655
|
16.13
|
10.65
|
7.915
|
9.322
|
9.322
|
9.322
|
P/E ratio
|
-
|
-1.09
x
|
-0.95
x
|
-0.41
x
|
-0.41
x
|
-1
x
|
-0.8
x
|
-0.76
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.29
x
|
31.9
x
|
-
|
47.6
x
|
1.61
x
|
1.35
x
|
3.25
x
|
-
|
EV / Revenue
|
1.29
x
|
31.9
x
|
-
|
47.6
x
|
1.61
x
|
1.35
x
|
3.25
x
|
-
|
EV / EBITDA
|
-3.28
x
|
-1.14
x
|
-1.36
x
|
-0.56
x
|
-0.62
x
|
-0.93
x
|
-0.79
x
|
-
|
EV / FCF
|
-
|
-1,132,254
x
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
8.03
x
|
4.5
x
|
1.5
x
|
1.29
x
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
251
|
319
|
1,024
|
2,240
|
4,523
|
4,276
|
-
|
-
|
Reference price
2 |
36.00
|
30.30
|
15.75
|
4.755
|
1.750
|
2.180
|
2.180
|
2.180
|
Announcement Date
|
3/30/20
|
2/22/21
|
2/24/22
|
2/23/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.998
|
0.303
|
-
|
0.224
|
4.913
|
6.927
|
2.867
|
-
|
EBITDA
1 |
-2.761
|
-8.437
|
-11.85
|
-19.09
|
-12.69
|
-10
|
-11.8
|
-
|
EBIT
1 |
-3.657
|
-9.584
|
-12.49
|
-19.71
|
-13.32
|
-17.71
|
-31.69
|
-55.35
|
Operating Margin
|
-52.26%
|
-3,163.04%
|
-
|
-8,800%
|
-271.14%
|
-255.66%
|
-1,105.49%
|
-
|
Earnings before Tax (EBT)
1 |
-10.89
|
-8.241
|
-13.4
|
-20.28
|
-13.32
|
-17.66
|
-31.66
|
-55.35
|
Net income
1 |
-11.44
|
-8.241
|
-13.4
|
-20.28
|
-13.32
|
-17.66
|
-31.66
|
-55.35
|
Net margin
|
-163.49%
|
-2,719.8%
|
-
|
-9,051.34%
|
-271.04%
|
-254.99%
|
-1,104.32%
|
-
|
EPS
2 |
-
|
-27.90
|
-16.65
|
-11.55
|
-4.240
|
-2.190
|
-2.733
|
-2.875
|
Free Cash Flow
|
-
|
-8.527
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-2,814.19%
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/20
|
2/22/21
|
2/24/22
|
2/23/23
|
3/5/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
0.073
|
0.151
|
0.506
|
1.854
|
1.24
|
1.313
|
1.677
|
1.75
|
1.75
|
1.75
|
1.65
|
1.65
|
EBITDA
1 |
-3.578
|
-3.779
|
-4.965
|
-4.936
|
-5.413
|
-4.422
|
-1.33
|
-2.944
|
-3.709
|
-2.998
|
-2.5
|
-2.5
|
-2.5
|
-2.7
|
-2.7
|
EBIT
1 |
-3.957
|
-3.926
|
-5.12
|
-5.094
|
-5.572
|
-4.72
|
-1.49
|
-3.251
|
-3.86
|
-3.299
|
-3.298
|
-3.371
|
-3.445
|
-5.461
|
-6.264
|
Operating Margin
|
-
|
-
|
-
|
-6,978.08%
|
-3,690.07%
|
-932.81%
|
-80.37%
|
-262.18%
|
-293.98%
|
-196.72%
|
-188.46%
|
-192.63%
|
-196.86%
|
-330.97%
|
-379.64%
|
Earnings before Tax (EBT)
1 |
-4.155
|
-4.116
|
-5.282
|
-5.219
|
-5.658
|
-4.805
|
-1.482
|
-3.219
|
-3.81
|
-3.261
|
-3.298
|
-3.371
|
-3.445
|
-5.461
|
-6.264
|
Net income
1 |
-4.155
|
-4.116
|
-5.282
|
-5.219
|
-5.658
|
-4.805
|
-1.482
|
-3.219
|
-3.81
|
-3.261
|
-3.298
|
-3.371
|
-3.445
|
-5.461
|
-6.264
|
Net margin
|
-
|
-
|
-
|
-7,149.32%
|
-3,747.02%
|
-949.6%
|
-79.94%
|
-259.6%
|
-290.18%
|
-194.45%
|
-188.46%
|
-192.63%
|
-196.86%
|
-330.97%
|
-379.64%
|
EPS
2 |
-3.750
|
-2.850
|
-3.600
|
-2.850
|
-2.400
|
-2.100
|
-0.5900
|
-1.000
|
-0.7000
|
-0.7500
|
-0.5200
|
-0.4200
|
-0.4200
|
-0.7250
|
-0.7200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/24/22
|
4/21/22
|
7/21/22
|
10/20/22
|
2/23/23
|
4/20/23
|
8/14/23
|
10/31/23
|
3/5/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-8.53
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
4.480
|
6.740
|
10.50
|
3.680
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.07
|
0.09
|
0.14
|
0.51
|
0.16
|
0.2
|
0.63
|
0.31
|
Capex / Sales
|
0.96%
|
30.69%
|
-
|
227.23%
|
3.26%
|
2.92%
|
21.92%
|
-
|
Announcement Date
|
3/30/20
|
2/22/21
|
2/24/22
|
2/23/23
|
3/5/24
|
-
|
-
|
-
|
Last Close Price
2.18
USD Average target price
16.5
USD Spread / Average Target +656.88% Consensus |
1st Jan change
|
Capi.
|
---|
| +24.56% | 9.32M | | +41.79% | 54.04B | | -0.56% | 41.92B | | +47.19% | 41.96B | | -7.20% | 28.35B | | +12.59% | 26.35B | | -21.51% | 19B | | +6.92% | 13B | | +24.91% | 12.19B | | +29.60% | 12.28B |
Other Biotechnology & Medical Research
|